DEXEMCIP, DEXMED, DEXMEDETOMIDINE CIPLA (Cipla Australia Pty Ltd)
Product name
DEXEMCIP, DEXMED, DEXMEDETOMIDINE CIPLA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
157 working days (255)
Active ingredients
dexmedetomidine hydrochloride
Registration type
New generic medicine
Indication
DEXEMCIP, DEXMED, DEXMEDETOMIDINE CIPLA (solution for injection) is indicated for:
Intensive care unit (ICU) sedation
Sedation of initially intubated patients during treatment in an intensive care setting. The use of DEXEMCIP by continuous infusion in these patients should not exceed 24 hours.
Procedural sedation
Sedation of non-intubated patients prior to and/or during surgical and other procedures.